Although blocking the PD-1/PD-L1 pathway can reactivate anti-tumor T cells, it also upregulates PD-1 expression, targeting PTEN-dependent signaling and enhancing transcription of oncogenic pathways such as PI3K/AKT and TGF-β, thereby contributing to HPD (35). This evidence concerns the gene CD274 and neoplasm.